The growing importance of pharmacoeconomics: The case of age-related macular degeneration

British Journal of Ophthalmology

Volumn 94, Issue 9, 2010, Pages 1116-1117

  Smith, A F ^a  

^a Medmetrics Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VERTEPORFIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

COST EFFECTIVENESS ANALYSIS; EDITORIAL; HEALTH CARE COST; HUMAN; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; ANIMAL; COST BENEFIT ANALYSIS; ECONOMICS; MACULAR DEGENERATION; PHARMACOECONOMICS; POPULATION DYNAMICS; PREVALENCE; RABBIT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; MACULAR DEGENERATION; POPULATION DYNAMICS; PREVALENCE; RABBITS; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77956582050     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.179945     Document Type: Editorial

References (15)

1. http://www.un.org/esa/population/publications/worldageing19502050/pdf/ 80chapterii.pdf (accessed 1 Apr 2010).
2. http://esa.un.org/unpd/wpp2008/peps-population-by-age-and-sex-5x1.htm (accessed 2 Apr 2010).
3. Friedman DS, O'Colmain BJ, Muñoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthmol 2004;122:564-72. (Pubitemid 38456293)
4. Appleby J, Devlin N, Parkin D. NICE's cost-effectiveness threshold: how high should it be? BMJ 2007;335:358-9.
5. Raftery J, Clegg A, Jones J, et al. Ranibizumal (Lucentis) versus bevaizumab (Avastin): modelling cost-effectiveness. Br J Ophthalmol 2007:91:1244-6.
6. Brown MM, Brown GC, Brown HC, et al. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2008;115:1039-45.
7. Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resour Alloc 2008;6:12-23.
8. Colquitt JL, Jones J, Sc Tan, et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2008;12:iiieiv, ixe201.
9. Hernández-Pastor LJ, Ortega A, Garcia-Layana A, et al. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2010;248:467-76.
10. Gower EW, Cassard SD, Bass EB, et al. A cost-effectiveness analysis of three treatments for age-related macular degeneration. Retina 2010;30:212-21.
11. Brown GC, Brown MM, Campanella J, et al. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration - a value-based reappraisal with 5-year data. Am J Ophthalmol 2005:140:679-87.
12. Brown GC, Brown MM, Brown HC, et al. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology 2007;114:1170-8.
13. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-9.
14. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-82.
15. Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol 2009;148:647-56.